March 11 Conf. Call About New Drug Added to Lapatinib + Capecitabine Trial

[Cynthia]

Friends,

I received this by email today. I personally know nothing about this trial, but thought I would post the information about the conference call in case any one is interested. Please note that the posted time for the call is Central Time.

You are cordially invited to join Dr. Paul Haluska in a teleconference for an update on and to discuss your questions/comments about the North Central Cancer Treatment Group Trial N0733 for HER2 positive breast cancer patients who have had their cancer back or grow through first line treatment with Herceptin. In this trial, we are adding a new drug (IMC-A12- an IGF-1R inhibitor) to the standard therapy for this patient population (Lapatinib + capecitabine). Pre-clinical experience indicates that this combination is mush better than the sum of the parts.

To join the call on March 11 at 2 p.m. CST, please use this toll-free conference call guideline:

Wednesday, March 11, 2-3 p.m. Central Standard Time

Please call:
Global Crossing: 1-866-365-4406; Participant Code: 2844481

If you know others who may be interested in joining the call, please share this invitation with them. We look forward to a spirited discussion.

Thanks,
Paul Haluska and Cynthia Chauhan